論文 - 詳細
| RRC ID | 72937 |
|---|---|
| 著者 | Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T. |
| タイトル | Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. |
| ジャーナル | J Pathol |
| Abstract |
Small cell lung cancer (SCLC) is characteristically not associated with tumour-infiltrating lymphocytes. Since SCLC has been reported to show marked reduction of class I HLA, the reduced expression has been considered a means of escaping anti-cancer immunity. However, HLA-DR expressed in cancer cells is now known to contribute to anti-cancer immunity. To clarify the difference in HLA-DR expression between SCLC and non-small cell lung cancer (NSCLC), and the mechanism, the expression and the cis- and trans-acting factors involved were investigated. HLA-DR was not immunohistochemically detected in any SCLC and could not be induced by interferon gamma (IFN-gamma) in any SCLC cell line, whereas HLA-DR was expressed to varying degrees and was easily induced in NSCLC. SCLC cell lines lacked class II transactivator (CIITA) even after IFN-gamma induction, whereas NSCLC cell lines expressed CIITA. The other class II HLA-specific transcription factors were expressed and genomic DNA of HLA-DR, including the promoter, was conserved well both in SCLC and in NSCLC cell lines. CIITA transfection improved the expression of HLA-DR in SCLC. In conclusion, the lack of CIITA results in severe deficiency of HLA-DR expression in SCLC. Since CIITA has also been reported to induce class I HLA, CIITA transfection might make it possible to establish effective anti-cancer immunotherapy against SCLC through the up-regulation of class I and class II HLA. |
| 巻・号 | 187(2) |
| ページ | 191-9 |
| 公開日 | 1999-1-1 |
| DOI | 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3 |
| PII | 10.1002/(SICI)1096-9896(199901)187:2<191::AID-PATH206>3.0.CO;2-3 |
| PMID | 10365094 |
| MeSH | Blotting, Northern Blotting, Southern Carcinoma, Non-Small-Cell Lung / immunology Carcinoma, Small Cell / genetics Carcinoma, Small Cell / immunology* Gene Expression HLA-DR Antigens / genetics HLA-DR Antigens / metabolism* Humans Interferon-gamma / immunology Lung Neoplasms / genetics Lung Neoplasms / immunology* Nuclear Proteins* RNA, Messenger / genetics Recombinant Proteins Trans-Activators / deficiency* Trans-Activators / genetics Transfection Tumor Cells, Cultured |
| IF | 6.021 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 7 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | SCLC cell lines (Lu cells) |